<DOC>
	<DOCNO>NCT00443352</DOCNO>
	<brief_summary>This single-center , open-label , pilot trial collect evaluate data safety efficacy duloxetine preventive treatment subject experience episodic migraine headache . Following 28-day baseline period , qualify subject enter 84-day treatment period . Subjects titrate first four week dose 120mg maximally tolerate dose ( MTD ) . The dose adjustment base individual subject response and/or subject 's tolerability . Subjects maintain daily diary capturing detailed information migraine headache day .</brief_summary>
	<brief_title>A Research Study Examining The Use Of Duloxetine In The Prevention Of Migraine Headache</brief_title>
	<detailed_description>Pharmacologic therapy migraine headache divide two type : acute treatment prophylactic treatment . Acute headache medication intend relieve pain disability acute attack stop progression . Prophylactic ( preventive ) headache therapy generally give daily , even absence headache , reduce frequency perhaps severity anticipated attack . Subjects experience recur migraine attack significantly interfere subject 's daily routine despite acute treatment , may warrant chronic prophylactic treatment . Duloxetine may important treatment option million unsuccessfully treat migraine patient therefore warrant study . Considering , propose single-center , open-label pilot trial collect evaluate data safety efficacy duloxetine preventive treatment subject episodic migraine headache . The result pilot trial provide preliminary insight clinical role duloxetine may play treatment headache , well provide basis future well-controlled trial medication . This single-center , open-label , pilot trial collect evaluate data safety efficacy duloxetine preventive treatment subject experience episodic migraine headache . Following 28-day baseline period , qualify subject enter 84-day treatment period . Subjects titrate first four week dose 120mg maximally tolerate dose ( MTD ) . The dose adjustment base individual subject response and/or subject 's tolerability . Subjects maintain daily diary capturing detailed information migraine headache day .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Subject male female age 18 65 , inclusive Subject IHS diagnosis migraine without aura least oneyear prior screening Subject experience 4 10 migraine headache per month ( inclusive ) past six month , least 24 hour separate attack Subject le 15 total headache day per month Subject able differentiate migraine attack headache type , applicable Subjects daily medication ( indication ) remain stable dose 60 day precede screen Subject use agrees use duration participation medically acceptable form contraception ( determined investigator mutually agree upon patient ) , female childbearing potential Subjects currently take single agent prevention migraine must stable dose ( unchanged 2 month ) prior study entry Subject negative urine pregnancy test prior study entry , female childbearing potential Subject able understand comply study requirement Subject provide write informed consent prior screen procedure conduct EXCLUSION CRITERIA : Subjects onset migraine 50 year age Subjects previously treat currently treat duloxetine Subjects fail great 3 adequate trial medication prevention migraine , determine investigator Subjects know hypersensitivity duloxetine inactive ingredient Subject take medication show effective migraine prophylaxis , daily basis within 4 week prior screen time participation study , indication . Subjects history significant drug alcohol abuse within past year Subjects major depressive disorder suicidal ideation 3 month prior screen history attempt suicide Subjects Beck Depression Inventory score &gt; 18 screen Subjects &gt; 0 question number 9 Beck Depression Inventory ( Suicidal Thoughts Wishes question ) Subjects participated investigational drug trial 30 day prior screen visit Subjects current history hepatic renal disorder Subjects uncontrolled narrow angle glaucoma Subjects experience significant side effect two different SSRI and/or SNRI therapy , determine investigator Subjects uncontrolled restless legs syndrome , determine investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>